This study is designed to assess whether co-administration of CP-690,550 and oral contraceptives will effect the metabolism of the oral contraceptives in healthy volunteers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID
Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone
Pfizer Investigational Site
Brussels, Belgium
AUCinf of ethinyloestradiol (EE) and levonorgestrel (LN)
Time frame: 12 days
AUClast, Cmax, Tmax, and t½ of ethinyloestradiol (EE) and levonorgestrel (LN)
Time frame: 12 days
Number of adverse events and number of participants with adverse events
Time frame: 12 days
Changes in complete blood count and serum chemistry profile
Time frame: 12 days
Changes in vital signs
Time frame: 12 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.